Jazz Pharmaceuticals (JAZZ) PT Lowered to $186 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $215.98 +3.92%
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
BofA Securities analyst Jason Gerberry lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $186.00 (from $210.00) while maintaining a Buy rating.
You May Also Be Interested In
- Jazz Pharmaceuticals (JAZZ) PT Raised to $300 at JPMorgan
- e.l.f. Beauty (ELF) PT Raised to $100 at Piper Sandler
- Regeneron Pharma (REGN) PT Raised to $1,020 at Raymond James
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
